ClinicalTrials.gg
Enrolling by invitationNCT06888661Updated Mar 21, 2025

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

An Early Phase 1 interventional study of EXG001-307 injection in Spinal Muscular Atrophy (SMA), sponsored by Hangzhou Jiayin Biotech Ltd. Enrolling by invitation at 2 sites in China. Open to participants aged 1 Day to 2 Years. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Hangzhou Jiayin Biotech Ltd · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
1 Day to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.

Planned enrollment
16th of 16
4 · median 35
Started
2025
with 3 others
Phase 1
Only one
of the 23
Primary completion
2026-03
later than 0 of 12 live
Registered
18th of 23
by date
Lead sponsor
2 of 23
Hangzhou Jiayin Biotech Ltd

Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the 16th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 1, reaches primary completion later than 0 of the 12 other live ones, and was the 18th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 1 Day to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy, Spinal with a site in China, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of EXG001-307 as a treatment of spinal muscular atrophy .

03

Conditions studied

  • Spinal Muscular Atrophy (SMA)

Keywords

  • SMA
  • AAV9
  • gene therapy
04

Who can participate

Ages eligible
1 Day to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. On the day of dosing, type 1 SMA age ≤180 days, type 2 SMA age > 180 days ≤2 years, male or female.
  2. Clinical history and physical signs are consistent with SMA manifestations; SMA was diagnosed by bilateral allelic SMN1 mutation (deletion or point mutation). Type 1 has 2 copies of SMN2 gene. Type 2 has ≤3 copies of SMN2 gene.

4.The subject's legal guardian understands the purpose, possible risks and interests of the study, agrees to participate in the study, completes all study procedures, tests and visits, and voluntarily signs the form.

5.During the study, the subject's legal guardian was willing to perform standard treatment requirements such as nasogastric feeding, noninvasive mechanical ventilation, and expectoration machine as recommended by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. The presence of to lumbar puncture (including, but not limited to, signs or symptoms of skin infection at the administration site and elevated intracranial pressure), the receipt of any active intrathecal therapy, the presence of an implantable shunt tube for draining CSF, the presence of an implantable central nervous system (CSF) cannula, or any condition that interferes with CSF collection.
  2. Imaging shows severe scoliosis (defined as curvature of the spine ≥ 50°).
  3. Gestational age at birth was less than 35 weeks (245 days).
  4. At screening, the subject had an oxygen saturation \< 95% while awake or sleeping and did not receive any supplemental oxygen or respiratory support.
  5. Requirement of invasive ventilation or tracheotomy, or current use of noninvasive ventilatory support for an average of ≥ 12 hours/day.
  6. Weighed below the 3rd percentile by age according to the WHO Child Growth Criteria (WHO 2009).
  7. Before administration, if the subject has not received or delayed vaccination according to the current month-old national vaccination plan, it will significantly affect the safety of the subject as assessed by the investigator and the medical manager of the project team;
  8. Active viral infections (including , or C seropositivity, torch virus, Epstein-Barr virus, and syphilis).
  9. Serious non-respiratory disease within 2 weeks prior to screening.
  10. EXG001-307 has had an upper respiratory tract infection or lower respiratory tract infection within 4 weeks prior to administration, and still has relevant clinical symptoms or is still in an unstable state of disease.
  11. Other severe infections or illnesses within 4 weeks prior to administration of EXG001-307.
  12. A history of bacterial meningitis or brain or spinal cord disease, including tumors, or abnormalities found on an MRI or computed tomography scan that interfere with a lumbar puncture procedure or cerebrospinal fluid circulation.
  13. There are currently heart disease or abnormalities that may affect the safety assessment of subjects.
  14. Known to prednisolone, other , or its ;Or cannot tolerate oral or gastrostomy tube administration of corticosteroids.
  15. therapy (eg, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, rituximab) other than protocol-required prophylaxis within 3 months prior to dosing.
  16. Immunomodulatory drugs (eg, thymosin, interferon, etc.) are being used to treat myopathy, neuritis, diabetes mellitus (eg, immunosuppressants, glucocorticoids, insulin).
  17. Prior use of other SMA therapeutic agents (e.g., nosinasenat, rispolam, and Zolgensma, etc.) or participated in clinical studies with other SMA therapeutic agents.
  18. Patients with type 2 SMA who had undergone scoliosis surgery or coxopexy in the 12 months prior to screening or were scheduled to undergo scoliosis surgery or coxopexy in the next 52 weeks.
  19. Major surgery is expected during study treatment.
  20. Other circumstances that, in the judgment of the investigator, are not suitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Dose escalation- Cohort 1

    Dose 1 Intrathecal administration dose 1 of EXG001-307 to SMA patient (type I \&type II)

    Biological: EXG001-307 injection

Interventions

  • BiologicalEXG001-307 injection

    non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of EXG001-307 following a single intrathecal injection

    Adverse events (AES), serious adverse events (SAEs), dose-limited toxicity types, severity, incidence, and drug relevance were evaluated after treatment.(Evaluate through examinations such as electrocardiogram, echocardiography, blood routine, blood biochemistry, coagulation function, etc. conducted during each visit)

    Time frame: up to 52 weeks after treatment

Secondary outcomes

  1. Evaluate the improvement of motor function in subjects after treatment: assessed with the BSID-III scale

    The achievement of new milestones in the BSID-III

    Time frame: up to 52 weeks after treatment

  2. Evaluate the improvement of motor function in subjects after treatment: assessed with the CHOP-INTEND scale

    Evaluate the changes in subjects' scores compared to baseline and the proportion of subjects with scores above 40 using the CHOP-INTEND scale.

    Time frame: up to 52 weeks after treatment

  3. Evaluate the improvement of motor function in subjects after treatment: assessed with the HINE-2 scale

    Evaluate the achievement of motor milestones by the Hammersmith Infant Neurological Examination (HINE-2) Module 2

    Time frame: up to 52 weeks after treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 21, 2025
StartEst.
Mar 10, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888661
Lead sponsor
Hangzhou Jiayin Biotech Ltd
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Mar 10, 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 21, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion